Effectiveness and Safety of the Novel Selective Urate Reabsorption Inhibitor Dotinurad After Switching from Febuxostat in Patients with Stage B/C Heart Failure
Switching from febuxostat to dotinurad may be effective and safe over the short term in patients with Stage B/C heart failure and hyperuricemia.
Authors
- Yuji Ikari (ORCID: https://orcid.org/0000-0001-5686-4324)
- Yuki Watanabe (ORCID: https://orcid.org/0000-0002-4258-4329)
- Tsutomu Murakami (ORCID: https://orcid.org/0000-0002-5164-1620)
- Norihito Nakamura (ORCID: https://orcid.org/0000-0002-5288-9222)
- Shigemitsu Tanaka
Institutions
- Tokai University (JP)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1007/s40801-025-00526-6
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00